These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16151477)

  • 41. A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma.
    O I; Blaszczyk-Thurin M; Shen CT; Ertl HC
    Cancer Gene Ther; 2003 Sep; 10(9):678-88. PubMed ID: 12944987
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
    Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X
    Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells.
    Kuriyama H; Shimizu K; Lee W; Kjaergaard J; Parkhurst MR; Cohen PA; Shu S
    Dev Biol (Basel); 2004; 116():169-78; discussion 179-86. PubMed ID: 15603192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice.
    Chen L; Tang XD; Yu ST; Ai ZH; Fang DC; Cai YG; Luo YH; Liang GP; Yang SM
    J Pathol; 2009 Apr; 217(5):685-92. PubMed ID: 19142972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.
    Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD
    Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma.
    O-Sullivan I; Kim TS; Chopra A; Cohen EP
    Anticancer Res; 2006; 26(2A):873-84. PubMed ID: 16619482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1.
    Riemann H; Takao J; Shellman YG; Hines WA; Edwards CK; Franzusoff A; Norris DA; Fujita M
    Exp Dermatol; 2007 Oct; 16(10):814-22. PubMed ID: 17845213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
    Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
    Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein.
    Rüttinger D; Li R; Poehlein CH; Haley D; Walker EB; Hu HM; Fox BA
    J Immunother; 2008 Jan; 31(1):43-51. PubMed ID: 18157011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biolistic DNA vaccination against melanoma.
    Steitz J; Tüting T
    Methods Mol Biol; 2013; 940():317-37. PubMed ID: 23104352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
    J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD4 T cell dependent tumor immunity stimulated by dendritic cell based vaccine.
    Zhang S; Li W; Xia Z; Mao Y
    Biochem Biophys Res Commun; 2011 Sep; 413(2):294-8. PubMed ID: 21893031
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
    Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.